InvestorsHub Logo
Followers 42
Posts 1152
Boards Moderated 0
Alias Born 03/24/2021

Re: OneMore2020 post# 136202

Sunday, 12/19/2021 8:20:01 PM

Sunday, December 19, 2021 8:20:01 PM

Post# of 198947
It looks to me like Samsung is positioning itself as a go-to manufacturer of bio companies' products, in particular for the purpose of clinical trials and FDA approval.

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. For more information, visit www.samsungbiologics.com . source



That they'd be willing to work with ENZC is great news! It also looks like they're willing to work with other biotechs. I'm not reading further into the ENZC/Samsung partnership than that ENZC would have a reliable mainstream CDMO to help maintain stability of drug manufacturing when that time comes. In other words, it's not an acquisition - I don't think Samsung sees ENZC's tech as a way to make Samsung a Big Pharma competitor to Moderna/Pfizer/Gilead/etc. Samsung is a for-hire drug factory in their partnership.